The Library
Profiling interactions of vaborbactam with metallo-β-lactamases
Tools
Tools
Tools
Langley, Gareth W., Cain, Ricky, Tyrrell, Jonathan M., Hinchliffe, Philip, Calvopiña, Karina, Tooke, Catherine L., Widlake, Emma, Dowson, Christopher G., Spencer, James, Walsh, Timothy R., Schofield, Christopher J. and Brem, Jürgen (2019) Profiling interactions of vaborbactam with metallo-β-lactamases. Bioorganic & Medicinal Chemistry Letters, 29 (15). pp. 1981-1984. doi:10.1016/j.bmcl.2019.05.031
|
PDF
WRAP-profiling-interactions-vaborbactam-Cain-2019.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1850Kb) | Preview |
Official URL: http://dx.doi.org/10.1016/j.bmcl.2019.05.031
Abstract
β-Lactams are the most successful antibacterials, yet their use is threatened by resistance, importantly as caused by β-lactamases. β-Lactamases fall into two mechanistic groups: the serine β-lactamases that utilise a covalent acyl-enzyme mechanism and the metallo β-lactamases that utilise a zinc-bound water nucleophile. Achieving simultaneous inhibition of both β-lactamase classes remains a challenge in the field. Vaborbactam is a boronate-based inhibitor that reacts with serine-β-lactamases to form covalent complexes that mimic tetrahedral intermediates in catalysis. Vaborbactam has recently been approved for clinical use in combination with the carbapenem meropenem. Here we show that vaborbactam moderately inhibits metallo-β-lactamases from all 3 subclasses (B1, B2 and B3), with a potency of around 20–100 fold below that by which it inhibits its current clinical targets, the Class A serine β-lactamases. This result contrasts with recent investigations of bicyclic boronate inhibitors, which potently inhibit subclass B1 MBLs but which presently lack activity against B2 and B3 enzymes. These findings indicate that cyclic boronate scaffolds have the potential to inhibit the full range of β-lactamases and justify further work on the development of boronates as broad-spectrum β-lactamase inhibitors.
| Item Type: | Journal Article | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | Q Science > QR Microbiology R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica |
||||||||||||||||||||||||
| Divisions: | Faculty of Science > Life Sciences (2010- ) | ||||||||||||||||||||||||
| Library of Congress Subject Headings (LCSH): | Beta lactam antibiotics , Beta lactamases -- Inhibitors, Drug resistance in microorganisms | ||||||||||||||||||||||||
| Journal or Publication Title: | Bioorganic & Medicinal Chemistry Letters | ||||||||||||||||||||||||
| Publisher: | Pergamon-Elsevier Science Ltd. | ||||||||||||||||||||||||
| ISSN: | 0960-894X | ||||||||||||||||||||||||
| Official Date: | 17 May 2019 | ||||||||||||||||||||||||
| Dates: |
|
||||||||||||||||||||||||
| Date of first compliant deposit: | 20 June 2019 | ||||||||||||||||||||||||
| Volume: | 29 | ||||||||||||||||||||||||
| Number: | 15 | ||||||||||||||||||||||||
| Page Range: | pp. 1981-1984 | ||||||||||||||||||||||||
| DOI: | 10.1016/j.bmcl.2019.05.031 | ||||||||||||||||||||||||
| Status: | Peer Reviewed | ||||||||||||||||||||||||
| Publication Status: | Published | ||||||||||||||||||||||||
| Access rights to Published version: | Open Access | ||||||||||||||||||||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
